Home Hepatitis The evolution and clinical impact of hepatitis B virus genome diversity

The evolution and clinical impact of hepatitis B virus genome diversity

Credits to the Source Link Daniel
The evolution and clinical impact of hepatitis B virus genome diversity
  • 1.

    Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).

  • 2.

    World Health Organization. Global Hepatitis Report, 2019 https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (WHO, 2017).

  • 3.

    Parkin, D. M. Global cancer statistics in the year 2000. Lancet Oncol. 2, 533–543 (2001).

  • 4.

    Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545–558 (2019).

  • 5.

    Alter, H. et al. A research agenda for curing chronic hepatitis B virus infection. Hepatology 67, 1127–1131 (2018).

  • 6.

    Revill, P., Testoni, B., Locarnini, S. & Zoulim, F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 13, 239–248 (2016). First ‘call to arms’ for hepatitis B cure, that led to the formation of the International Coalition to Eliminate Hepatitis B (ICE-HBV).

  • 7.

    Wei, L. & Lok, A. S. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 146, 1145–1150 (2014).

  • 8.

    Salpini, R. et al. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: evidence of a relevant risk of death and evolution from silent to chronic infection. J. Viral Hepat. 26, 846–855 (2019).

  • 9.

    Hoofnagle, J. H. Reactivation of hepatitis B. Hepatology 49, S156–S165 (2009).

  • 10.

    Comas, I. et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45, 1176–1182 (2013).

  • 11.

    Linz, B. et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 445, 915–918 (2007).

  • 12.

    Wolfe, N. D., Dunavan, C. P. & Diamond, J. Origins of major human infectious diseases. Nature 447, 279–283 (2007).

  • 13.

    Blaser, M. J. & Kirschner, D. The equilibria that allow bacterial persistence in human hosts. Nature 449, 843–84 (2007).

  • 14.

    Kahila Bar-Gal, G. et al. Tracing hepatitis B virus to the 16th century in a Korean mummy. Hepatology 56, 1671–1680 (2012). First report of ancient HBV genome isolated from ancient human remains, a 400-year-old Korean mummy.

  • 15.

    Patterson Ross, Z. et al. The paradox of HBV evolution as revealed from a 16th century mummy. PLoS Pathog. 14, e1006750 (2018).

  • 16.

    Muhlemann, B. et al. Ancient hepatitis B viruses from the Bronze age to the Medieval period. Nature 557, 418–423 (2018). First report of Bronze age HBV genomes extracted from a number of archaeological sites across Europe, including a now extinct human genotype.

  • 17.

    Krause-Kyora, B. et al. Neolithic and medieval virus genomes reveal complex evolution of hepatitis B. Elife 7, e36666 (2018).

  • 18.

    Yuen, L. K. W. et al. Tracing ancient human migrations into Sahul using hepatitis B virus genomes. Mol. Biol. Evol. 36, 942–954 (2019). First example of HBV evolution and diversity being used to trace human migration.

  • 19.

    MacLachlan, J. H. & Cowie, B. C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 5, a021410 (2015).

  • 20.

    Graham, S. et al. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis. BMC Infect. Dis. 13, 403 (2013).

  • 21.

    Parker, C. et al. Hepatocellular carcinoma in Australia’s Northern Territory: high incidence and poor outcome. Med. J. Aust. 201, 470–474 (2014).

  • 22.

    Ormaeche, M., Whittembury, A., Pun, M. & Suarez-Ognio, L. Hepatitis B virus, syphilis, and HIV seroprevalence in pregnant women and their male partners from six indigenous populations of the Peruvian Amazon Basin, 2007-2008. Int. J. Infect. Dis. 16, e724–e730 (2012).

  • 23.

    Viana, S., Parana, R., Moreira, R. C., Compri, A. P. & Macedo, V. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am. J. Trop. Med. Hyg. 73, 808–814 (2005).

  • 24.

    Schweitzer, A., Mmath, J. H., Mikolaiczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546–1555 (2015).

  • 25.

    Bouckaert, R., Simons, B. C., Krarup, H., Friesen, T. M. & Osiowy, C. Tracing hepatitis B virus (HBV) genotype B5 (formerly B6) evolutionary history in the circumpolar Arctic through phylogeographic modelling. PeerJ. 5, e3757 (2017).

  • 26.

    McMahon, B. J. et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54, 801–807 (2011).

  • 27.

    Robinson, T., Bullen, C., Humphries, W., Hornell, J. & Moyes, C. The New Zealand hepatitis B screening programme: screening coverage and prevalence of chronic hepatitis B infection. NZ Med. J. 118, U1345 (2005).

  • 28.

    Huang, C. F. et al. HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study. Prev. Med. 48, 397–400 (2009).

  • 29.

    Wilson, N., Ruff, T. A., Rana, B. J., Leydon, J. & Locarnini, S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. Vaccine 18, 3059–3066 (2000).

  • 30.

    McMahon, B. J. Viral hepatitis in the Arctic. Int. J. Circumpolar Health 63 (Suppl. 2), 41–48 (2004).

  • 31.

    Kramvis, A. Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus. S. Afr. Med. J. 108, S17–S21 (2018).

  • 32.

    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017). The current European Clinical Practice Guidelines for the management of hepatitis B virus infection.

  • 33.

    Bayliss, J. et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 66, 2013–2023 (2017).

  • 34.

    Sonneveld, M. J. et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 56, 67–75 (2012).

  • 35.

    Seeger, C., Zoulim, F. & Mason, W. S. in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2185–2221 (Lippincott Williams & Wilkins, 2013).

  • 36.

    International Committee on Taxonomy of Viruses. ICTV https://talk.ictvonline.org (2019).

  • 37.

    Hahn, C. M. et al. Characterization of a novel hepadnavirus in the white sucker (Catostomus commersonii) from the Great Lakes region of the United States. J. Virol. 89, 11801–11811 (2015).

  • 38.

    Dill, J. A. et al. Distinct viral lineages from fish and amphibians reveal the complex evolutionary history of hepadnaviruses. J. Virol. 90, 7920–7933 (2016).

  • 39.

    Littlejohn, M., Locarnini, S. & Yuen, L. Origins and evolution of hepatitis B virus and hepatitis D virus. Cold Spring Harb. Perspect. Med. 6, a021360 (2016). Detailed review summarizing and discussing current theories on the origin and evolution of HBV and HDV.

  • 40.

    Lauber, C. et al. Deciphering the origin and evolution of hepatitis B viruses by means of a family of non-enveloped fish viruses. Cell Host Microbe 22, 387–399 (2017).

  • 41.

    de Carvalho Dominguez Souza, B. F. et al. A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses. J. Hepatology 68, 1114–1122 (2018).

  • 42.

    Aghazadeh, M. et al. A novel hepadnavirus identified in an immunocompromised domestic cat in Australia. Viruses 10, E269 (2018).

  • 43.

    Geoghegan, J. L. et al. Hidden diversity and evolution of viruses in market fish. Virus Evol. 4, vey031 (2018).

  • 44.

    Gong, Z. & Han, G. Z. Insect retroelements provide novel insights into the origin of hepatitis B viruses. Mol. Biol. Evol. 35, 2254–2259 (2018).

  • 45.

    Gilbert, C. & Feschotte, C. Genomic fossils calibrate the long-term evolution of hepadnaviruses. PLoS Biol. 8, e1000495 (2010). First report of endogenous hepadnaviruses, discovered in the genome of the zebra finch.

  • 46.

    Gilbert, C. et al. Endogenous hepadnaviruses, bornaviruses and circoviruses in snakes. Proc. Biol. Sci. 281, 20141122 (2014).

  • 47.

    Suh, A. et al. Early mesozoic coexistence of amniotes and hepadnaviridae. PLoS Genet. 10, e1004559 (2014).

  • 48.

    Geoghegan, J. L., Duchene, S. & Holmes, E. C. Comparative analysis estimates the relative frequencies of co-divergence and cross-species transmission within viral families. PLoS Pathog. 13, e1006215 (2017).

  • 49.

    Drexler, J. F. et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc. Natl Acad. Sci. USA 110, 16151–16156 (2013). Report of the discovery of a number of HBV-like viruses in bats, including experiments showing that bat HBV can infect human hepatocytes.

  • 50.

    Wieland, S. F. The chimpanzee model for hepatitis B virus infection. Cold Spring Harb. Perspect. Med. 5, a021469 (2015).

  • 51.

    Dupinay, T. et al. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 58, 1610–1620 (2013).

  • 52.

    Dickens, C., Kew, M. C., Purcell, R. H. & Kramvis, A. Occult hepatitis B virus infection in chacma baboons, South Africa. Emerg. Infect. Dis. 19, 598–605 (2013).

  • 53.

    Tatematsu, K. et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J. Virol. 83, 10538–10547 (2009). Description of the single isolate of HBV ‘putative genotype’ J.

  • 54.

    Begun, D. R. Planet of the apes. Sci. Am. 289, 74–83 (2003).

  • 55.

    Begun, D. R., Nargolwalla, M. C. & Kordos, L. European Miocene hominids and the origin of the African ape and human clade. Evol. Anthropol. 21, 10–23 (2012).

  • 56.

    Zhou, Y. & Holmes, E. C. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J. Mol. Evol. 65, 197–205 (2007).

  • 57.

    Orito, E. et al. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc. Natl Acad. Sci. USA 86, 7059–7062 (1989).

  • 58.

    Paraskevis, D. et al. Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes. Mol. Phylogenet. Evol. 93, 44–54 (2015).

  • 59.

    Paraskevis, D. et al. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 57, 908–916 (2013).

  • 60.

    Tedder, R. S., Bissett, S. L., Myers, R. & Ijaz, S. The ‘Red Queen’ dilemma – running to stay in the same place: reflections on the evolutionary vector of HBV in humans. Antivir. Ther. 18, 489–496 (2013). An interesting paper outlining experiments confirming a theory explaining the slow evolutionary rate of human HBV.

  • 61.

    Simmonds, P. & Smith, D. B. in Viral Hepatitis 4th edn (eds Thomas, H. C., Lok, A. S. F., Locarnini, S. A. & Zuckerman, A. J.) 575–586 (Wiley, 2014).

  • 62.

    Simmonds, P., Aiewsakun, P. & Katzourakis, A. Prisoners of war – host adaptation and its constraints on virus evolution. Nat. Rev. Microbiol. 17, 321–328 (2018).

  • 63.

    Lim, S. G. et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 133, 951–958 (2007).

  • 64.

    Homs, M. et al. Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. PLoS One 9, e112306 (2014).

  • 65.

    Charuworn, P. et al. Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate. J. Hepatol. 62, 1033–1039 (2015).

  • 66.

    Kramvis, A. Genotypes and genetic variability of hepatitis B virus. Intervirology 57, 141–150 (2014). Excellent summary of human HBV genotype and sub-genotype classification, including a set of minimum criteria for future proposals of novel genotypes and sub-genotypes.

  • 67.

    Kim, B. K., Revill, P. A. & Ahn, S. H. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir. Ther. 16, 1169–1186 (2011).

  • 68.

    Chan, H. L. et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53, 1494–1498 (2004).

  • 69.

    Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst. 100, 1134–1143 (2008).

  • 70.

    Wong, G. L. et al. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment. Pharmacol. Ther. 37, 517–526 (2013).

  • 71.

    Kramvis, A. & Kew, M. C. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. Hepatol. Res. 37, S27–S32 (2007). First characterization of the African A1 HBV subgenotype describing specific sequence elements that may contribute to the increased risk of HCC in patients infected with HBV-A1.

  • 72.

    Gounder, P. P. et al. Hepatocellular carcinoma risk in Alaska native children and young adults with hepatitis B virus: retrospective cohort analysis. J. Pediatr. 178, 206–213 (2016).

  • 73.

    Orito, E. & Mizokami, M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol. Res. 37, S33–S35 (2007).

  • 74.

    Krarup, H. B. et al. Benign course of long-standing hepatitis B virus infection among Greenland Inuit? Scand. J. Gastroenterol. 43, 334–343 (2008).

  • 75.

    Minuk, G. Y. et al. A paucity of liver disease in Canadian Inuit with chronic hepatitis B virus, subgenotype B6 infection. J. Viral Hepat. 20, 890–896 (2013).

  • 76.

    Roman, S., Fierro, N., Moreno-Luna, L. & Panduro, A. Hepatitis B virus genotype H and environmental factors associated to the low prevalence of hepatocellular carcinoma in Mexico. J. Cancer Ther. 4, 367–376 (2013).

  • 77.

    Sozzi, V. et al. In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease. Virology 519, 190–196 (2018).

  • 78.

    Sozzi, V. et al. In vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes. J. Virol. 90, 10054–10064 (2016).

  • 79.

    Sugiyama, M. et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44, 915–924 (2006).

  • 80.

    Bhoola, N. H., Reumann, K., Kew, M. C., Will, H. & Kramvis, A. Construction of replication competent plasmids of hepatitis B virus subgenotypes A1, A2 and D3 with authentic endogenous promoters. J. Virol. Methods 203, 54–64 (2014).

  • 81.

    Flink, H. J. et al. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 101, 297–303 (2006).

  • 82.

    Buster, E. H. et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137, 2002–2009 (2009).

  • 83.

    Shen, F. et al. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype. Hepatology 67, 1237–1252 (2018).

  • 84.

    Marcellin, P. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442–2455 (2008).

  • 85.

    Bihl, F. et al. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 15, 79 (2015).

  • 86.

    Marcellin, P. et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J. Hepatol. 61, 1228–1237 (2014).

  • 87.

    Yao, C. C. et al. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci. Rep. 7, 1839 (2017).

  • 88.

    Chen, C. H. et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J. Hepatol. 61, 515–522 (2014).

  • 89.

    Kramvis, A., Kostaki, E. G., Hatzakis, A. & Paraskevis, D. Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of hepatitis B virus. Front. Microbiol. 9, 2521 (2018).

  • 90.

    Buckwold, V. E., Xu, Z., Chen, M., Yen, T. S. & Ou, J. H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845–5851 (1996).

  • 91.

    Warner, N. & Locarnini, S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48, 88–98 (2008).

  • 92.

    Kay, A. & Zoulim, F. Hepatitis B virus genetic variability and evolution. Virus Res. 127, 164–176 (2007).

  • 93.

    Zoulim, F. & Locarnini, S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 33 (Suppl. 1), 116–124 (2013).

  • 94.

    Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018). Most recent American HBV treatment guidelines from the AASLD.

  • 95.

    Littlejohn, M. Antiviral drug resistance and hepatitis B: a continuing public health problem. Antivir. Ther. 22, 643–644 (2017).

  • 96.

    Liu, Y. et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment. J. Viral Hepat. 24, 68–74 (2017).

  • 97.

    Park, E. S. et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J. Hepatol. 70, 1093–1102 (2019).

  • 98.

    Cathcart, A. L. et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection. Antimicrob. Agents Chemother. 62, e01064-18 (2018).

  • 99.

    Lok, A. S., Zoulim, F., Dusheiko, G. & Ghany, M. G. Hepatitis B cure: from discovery to regulatory approval. Hepatology 66, 1296–1313 (2017).

  • 100.

    Zeisel, M. B. et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 64, 1314–1326 (2015).

  • 101.

    Revill, P. A., Penicaud, C., Brechot, C. & Zoulim, F. Meeting the challenge of eliminating chronic hepatitis B infection. Genes 10, 260 (2019).

  • 102.

    Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26, 335–341 (2008).

  • 103.

    Thi, E. P. et al. ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection. ACS Infect. Dis. 5, 725–737 (2018).

  • 104.

    Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 9, eaan0241 (2017). Groundbreaking study demonstrating that in HBeAg-negative individuals, most of the secreted HBsAg is produced by RNA transcribed from integrated HBV DNA.

  • 105.

    Bazinet, M. et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 2, 877–889 (2017).

  • 106.

    Roehl, I. et al. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol. Ther. Nucleic Acids 8, 1–12 (2017).

  • 107.

    Long, K. R. et al. Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice. Antivir. Res. 149, 41–47 (2018).

  • 108.

    Klumpp, K. et al. Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir In uPA/SCID mice with humanized livers and HBV infection. Gastroenterology 154, 652–662 (2018).

  • 109.

    Lam, A. M. et al. Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus. Antimicrob. Agents Chemother. 63, e01734-18 (2019).

  • 110.

    Berke, J. M. et al. Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro. Antivir. Res. 144, 205–215 (2017).

  • 111.

    Ruan, L., Hadden, J. A. & Zlotnick, A. Assembly properties of hepatitis B virus core protein mutants correlate with their resistance to assembly-directed antivirals. J. Virol. 92, e01082-18 (2018).

  • 112.

    Wang, J. et al. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein. J. Med. Virol. 89, 1804–1810 (2017).

  • 113.

    Zhou, Z. et al. Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms. Sci. Rep. 7, 42374 (2017).

  • 114.

    Seeger, C. & Sohn, J. A. Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol. Ther. 24, 1258–1266 (2016).

  • 115.

    Carman, W. F. et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325–329 (1990).

  • 116.

    Carman, W. F. The clinical significance of surface antigen variants of hepatitis B virus. J. Viral Hepat. 4 (Suppl. 1), 11–20 (1997).

  • 117.

    Hsu, H. Y., Chang, M. H., Ni, Y. H. & Chen, H. L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53, 1499–1503 (2004).

  • 118.

    Wang, J. et al. Molecular evolution of hepatitis B vaccine escape variants in China, during 2000–2016. Vaccine 35, 5808–5813 (2017).

  • 119.

    Mokaya, J. et al. A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action. PLoS Negl. Trop. Dis. 12, e0006629 (2018).

  • 120.

    Locarnini, S. & Shouval, D. Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance. J. Virol. 88, 6532 (2014).

  • 121.

    Jilg, W. et al. Reduced prevalence of HBsAg variants following a successful immunization program in China. J. Virol. 88, 4605–4606 (2014).

  • 122.

    Tu, T., Buhler, S. & Bartenschlager, R. Chronic viral hepatitis and its association with liver cancer. Biol. Chem. 398, 817–837 (2017).

  • 123.

    Orito, E. et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34, 590–594 (2001).

  • 124.

    Orito, E. & Mizokami, M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 46, 408–412 (2003).

  • 125.

    Ding, X. et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 44, 43–47 (2001).

  • 126.

    Pan, M. H. et al. Hepatitis B splice variants are strongly associated with and are indeed predictive of hepatocellular carcinoma. J. Hepatol. 68, s474–s475 (2018).

  • 127.

    Bayliss, J. et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J. Hepatol. 59, 1022–1028 (2013). First study to identify an association between the presence of HBV splice variants in patient serum and liver cancer.

  • 128.

    Baptista, M., Kramvis, A. & Kew, M. C. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29, 946–953 (1999).

  • 129.

    Kao, J. H. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 46, 400–407 (2003).

  • 130.

    Fang, Z. L. et al. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J. Med. Virol. 56, 18–24 (1998).

  • 131.

    Kim, D. W., Lee, S. A., Hwang, E. S., Kook, Y. H. & Kim, B. J. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PLoS One 7, e47372 (2012).

  • 132.

    Ni, Y. H., Chang, M. H., Hsu, H. Y. & Tsuei, D. J. Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut 52, 122–125 (2003).

  • 133.

    Sung, F. Y. et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 137, 1687–1697 (2009).

  • 134.

    Liu, W. C. et al. Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J. Pathol. 243, 176–192 (2017).

  • 135.

    Yen, C. J. et al. Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology 68, 815–826 (2018).

  • 136.

    Tsai, H. W. et al. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. Oncotarget 7, 27724–27734 (2016).

  • 137.

    Yen, T. T. et al. Hepatitis B virus PreS2-mutant large surface antigen activates store-operated calcium entry and promotes chromosome instability. Oncotarget 7, 23346–23360 (2016).

  • 138.

    Hsieh, Y. H. et al. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis. J. Pathol. 236, 337–347 (2015).

  • 139.

    Lai, M. W. et al. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis 5, e273 (2016).

  • 140.

    Su, I. J., Wang, H. C., Wu, H. C. & Huang, W. Y. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 23, 1169–1174 (2008).

  • 141.

    Fan, Y. F. et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33, 277–286 (2001).

  • 142.

    Lamontagne, R. J., Bagga, S. & Bouchard, M. J. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2, 163–186 (2016).

  • 143.

    Salpini, R. et al. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin. Microbiol. Infect. 25, 906.e1–906.e7 (2019).

  • 144.

    Raimondo, G. et al. Occult hepatitis B virus infection. Dig. Liver Dis. 32, 822–826 (2000).

  • 145.

    Raimondo, G. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71, 397–408 (2019). Comprehensive summary on the importance of occult HBV infection.

  • 146.

    Ramachandran, S. et al. Recent and occult hepatitis B virus infections among blood donors in the United States. Transfusion 59, 601–611 (2019).

  • 147.

    Deguchi, M. et al. Evaluation of the highly sensitive chemiluminescent enzyme immunoassay ‘‘Lumipulse HBsAg-HQ’’ for hepatitis B virus screening. J. Clin. Lab. Anal. 32, e22334 (2018).

  • 148.

    Zhang, K. et al. Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection. J. Med. Virol. 90, 263–270 (2018).

  • 149.

    Hass, M. et al. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 42, 93–103 (2005).

  • 150.

    Huang, F. Y. et al. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One 9, e99028 (2014).

  • 151.

    Ponde, R. A. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1709–1731 (2015).

  • 152.

    McNaughton, A. L. et al. Insights from deep sequencing of the HBV genome — unique, tiny, and misunderstood. Gastroenterology 156, 384–399 (2019).

  • 153.

    Bill, C. A. & Summers, J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc. Natl Acad. Sci. USA 101, 11135–11140 (2004).

  • 154.

    Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221–1228 (2014).

  • 155.

    Nair, S. & Zlotnick, A. Asymmetric modification of hepatitis B virus (HBV) genomes by an endogenous cytidine deaminase inside HBV cores informs a model of reverse transcription. J. Virol. 92, e02190–17 (2018).

  • 156.

    Suspene, R. et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl Acad. Sci. USA 102, 8321–8326 (2005).

  • 157.

    Vartanian, J. P. et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 6, e1000928 (2010).

  • 158.

    Gout, J. F., Thomas, W. K., Smith, Z., Okamoto, K. & Lynch, M. Large-scale detection of in vivo transcription errors. Proc. Natl Acad. Sci. USA 110, 18584–18589 (2013).

  • 159.

    Imashimizu, M., Oshima, T., Lubkowska, L. & Kashlev, M. Direct assessment of transcription fidelity by high-resolution RNA sequencing. Nucleic Acids Res. 41, 9090–9104 (2013).

  • 160.

    Carey, L. B. RNA polymerase errors cause splicing defects and can be regulated by differential expression of RNA polymerase subunits. Elife 4, e09945 (2015).

  • 161.

    Park, S. G., Kim, Y., Park, E., Ryu, H. M. & Jung, G. Fidelity of hepatitis B virus polymerase. Eur. J. Biochem. 270, 2929–2936 (2003).

  • 162.

    Preikschat, P. et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 35, 466–477 (2002).

  • 163.

    Yeung, P. et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J. Infect. Dis. 203, 646–654 (2011).

  • 164.

    Zhao, X. L. et al. Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV. Gut 65, 502–511 (2016).

  • 165.

    Lewellyn, E. B. & Loeb, D. D. Base pairing between cis-acting sequences contributes to template switching during plus-strand DNA synthesis in human hepatitis B virus. J. Virol. 81, 6207–6215 (2007).

  • 166.

    Liu, N., Ji, L., Maguire, M. L. & Loeb, D. D. cis-Acting sequences that contribute to the synthesis of relaxed-circular DNA of human hepatitis B virus. J. Virol. 78, 642–649 (2004).

  • 167.

    Brechot, C., Gozuacik, D., Murakami, Y. & Paterlini-Brechot, P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin. Cancer Biol. 10, 211–231 (2000).

  • 168.

    Tu, T., Budzinska, M. A., Vondran, F. W. R., Shackel, N. A. & Urban, S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles. J. Virol. 92, e02007–17 (2018). This study changed the dogma that HBV integration only occurs late in chronic disease by demonstrating that HBV integration occurs very early after infection.

  • 169.

    Lan, P., Zhang, C., Han, Q., Zhang, J. & Tian, Z. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 58, 73–85 (2013).

  • 170.

    Michler, T. et al. Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol. Med. 8, 1082–1098 (2016).

  • 171.

    Li, B. et al. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo. Antivir. Res. 134, 117–129 (2016).

  • 172.

    Tu, T., Budzinska, M. A., Shackel, N. A. & Urban, S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 9, 75 (2017).

  • 173.

    Sommer, G. & Heise, T. Posttranscriptional control of HBV gene expression. Front. Biosci. 13, 5533–5547 (2008).

  • 174.

    Su, T. S. et al. Hepatitis B virus transcript produced by RNA splicing. J. Virol. 63, 4011–4018 (1989).

  • 175.

    Gunther, S., Sommer, G., Iwanska, A. & Will, H. Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology 238, 363–371 (1997).

  • 176.

    Chen, J. et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci. Rep. 5, 16459 (2015).

  • 177.

    Lam, A. M. et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob. Agents Chemother. 61, e00680-17 (2017).

  • 178.

    Ziemer, M., Garcia, P., Shaul, Y. & Rutter, W. J. Sequence of hepatitis B virus DNA incorporated into the genome of a human hepatoma cell line. J. Virol. 53, 885–892 (1985). One of the first studies showing HBV integration into the human genome.

  • 179.

    Soussan, P. et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J. Clin. Invest. 105, 55–60 (2000). First identification and characterization of a novel protein produced by HBV splice variants.

  • 180.

    Soussan, P. et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J. Infect. Dis. 198, 218–225 (2008).

  • 181.

    Soussan, P. et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J. Hepatol. 38, 343–348 (2003).

  • 182.

    Chen, W. N. et al. Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion. J. Virol. 86, 13533–13541 (2012).

  • 183.

    Shi, W. et al. Identification of novel inter-genotypic recombinants of human hepatitis B viruses by large-scale phylogenetic analysis. Virology 427, 51–59 (2012).

  • 184.

    Simmonds, P. & Midgley, S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J. Virol. 79, 15467–15476 (2005). This study was the first to demonstrate that significant recombination events occurred in the evolution of HBV.

  • 185.

    Yang, J., Xing, K., Deng, R., Wang, J. & Wang, X. Identification of hepatitis B virus putative intergenotype recombinants by using fragment typing. J. Gen. Virol. 87, 2203–2215 (2006).

  • 186.

    Bowyer, S. M. & Sim, J. G. Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates. J. Gen. Virol. 81, 379–392 (2000).

  • 187.

    Araujo, N. M. Hepatitis B virus intergenotypic recombinants worldwide: an overview. Infect. Genet. Evol. 36, 500–510 (2015).

  • 188.

    Sugauchi, F. et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J. Virol. 76, 5985–5992 (2002).

  • 189.

    Littlejohn, M. et al. Molecular virology of hepatitis B virus, sub-genotype C4 in northern Australian indigenous populations. J. Med. Virol. 86, 695–706 (2014). This is the first description of the sequence and characterization of the novel C4 subgenotype in indigenous Australian peoples.

  • 190.

    Cui, C. et al. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J. Gen. Virol. 83, 2773–2777 (2002).

  • 191.

    Cheng, Y., Guindon, S., Rodrigo, A. & Lim, S. G. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J. Hepatol. 58, 217–224 (2013).

  • 192.

    Wu, S. et al. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. J. Hepatol. 54, 19–25 (2011).

  • 193.

    Nie, H., Evans, A. A., London, W. T., Block, T. M. & Ren, X. D. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J. Hepatol. 56, 795–802 (2012).

  • 194.

    Stevens, C. E., Neurath, R. A., Beasley, R. P. & Szmuness, W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J. Med. Virol. 3, 237–241 (1979).

  • 195.

    Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, e00049 (2012). This is the first report of the identification and description of the HBV entry receptor — a major discovery for the HBV field.

  • 196.

    Meier, A., Mehrle, S., Weiss, T. S., Mier, W. & Urban, S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 58, 31–42 (2013).

  • 197.

    Hasegawa, K., Huang, J., Rogers, S. A., Blum, H. E. & Liang, T. J. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J. Virol. 68, 1651–1659 (1994).

  • 198.

    Baumert, T. F., Rogers, S. A., Hasegawa, K. & Liang, T. J. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J. Clin. Invest. 98, 2268–2276 (1996).

  • 199.

    Nishizawa, T. et al. Enhanced pregenomic RNA levels and lowered precore mRNA transcription efficiency in a genotype A hepatitis B virus genome with C1766T and T1768A mutations obtained from a fulminant hepatitis patient. J. Gen. Virol. 97, 2643–2656 (2016).

  • 200.

    Seeger, C. & Mason, W. S. Molecular biology of hepatitis B virus infection. Virology 479–480, 672–686 (2015).

  • 201.

    Tu, T. & Urban, S. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Curr. Opin. Virol. 30, 68–79 (2018).

  • 202.

    Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 67, 542–552 (2018).

  • 203.

    Farci, P. & Niro, G. A. Current and future management of chronic hepatitis D. Gastroenterol. Hepatol. 14, 342–351 (2018).

  • 204.

    Wranke, A. et al. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: the Hepatitis Delta International Network (HDIN). Liver Internatl. 38, 842–850 (2018).

  • 205.

    Magnius, L. et al. ICTV virus taxonomy profile: deltavirus. J. Gen. Virol. 99, 1565–1566 (2018).

  • 206.

    Le Gal, F. et al. Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains. Hepatology 66, 1826–1841 (2017).

  • 207.

    Ryu, W. S., Bayer, M. & Taylor, M. Assembly of hepatitis delta virus. J. Virol. 66, 2310–2315 (1992).

  • 208.

    Wang, C. J., Chen, P. J., Wu, J. C., Patel, D. & Chen, D. S. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. J. Virol. 65, 6630–6636 (1991).

  • 209.

    Polo, J. M. et al. Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle. J. Virol. 69, 4880–4887 (1995).

  • 210.

    Kristensen, L. S. et al. The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 675–691 (2019).

  • 211.

    Barrett, S. P. & Salzman, J. Circular RNAs: analysis, expression and potential functions. Development 143, 1838–1847 (2016).

  • 212.

    Perrotta, A. T. & Been, M. D. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350, 434–436 (1991).

  • 213.

    Ferre-D’Amare, A. R., Zhou, K. & Doudna, J. A. Crystal structure of a hepatitis delta virus ribozyme. Nature 395, 567–574 (1998).

  • 214.

    Webb, C. H., Nguyen, D., Myszka, M. & Luptak, A. Topological constraints of structural elements in regulation of catalytic activity in HDV-like self-cleaving ribozymes. Sci. Rep. 6, 28179 (2016).

  • 215.

    Webb, C. H. & Luptak, A. HDV-like self-cleaving ribozymes. RNA Biol. 8, 719–727 (2011).

  • 216.

    Salehi-Ashtiani, K., Luptak, A., Litovchick, A. & Szostak, J. W. A genomewide search for ribozymes reveals an HDV-like sequence in the human CPEB3 gene. Science 313, 1788–1792 (2006).

  • 217.

    Wille, M. et al. A divergent hepatitis D-like agent in birds. Viruses 10, E720 (2018).

  • 218.

    Hetzel, U. et al. Identification of a novel deltavirus in boa constrictors. MBio 10, e00014–19 (2019).

  • 219.

    Chang, W. S. et al. Novel hepatitis D-like agents in vertebrates and invertebrates. Virus Evol. 5, vez021 (2019).

  • 220.

    Perez-Vargas, J. et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat. Commun. 10, 2098 (2019).

  • 221.

    Weller, M. L. et al. Hepatitis delta virus detected in salivary glands of Sjögren’s syndrome patients and recapitulates a Sjögren’s syndrome-like phenotype in vivo. Pathog. Immun. 1, 12–40 (2016).

  • 222.

    Szirovicza, L. et al. Snake deltavirus utilizes envelope proteins of different viruses to generate infectious particles. MBio 11, e03250-19 (2019).

  • 223.

    Rizzetto, M. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb. Perspect. Med. 5, a021576 (2015).

  • 224.

    Wang, T. C. & Chao, M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J. Virol. 79, 2221–2229 (2005).

  • 225.

    Lin, C. C. et al. RNA recombination in hepatitis delta virus: identification of a novel naturally occurring recombinant. J. Microbiol. Immunol. Infect. 50, 771–780 (2017).

  • 226.

    Hsu, S. C. et al. Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications. Hepatology 35, 665–672 (2002).

  • 227.

    Wu, J. C. et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 346, 939–941 (1995).

  • 228.

    Ivaniushina, V. et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J. Gen. Virol. 82, 2709–2718 (2001).

  • 229.

    Casey, J. L. et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J. Infect. Dis. 174, 920–926 (1996).

  • 230.

    Watanabe, H. et al. Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J. Gen. Virol. 84, 3275–3289 (2003).

  • 231.

    Madejon, A. et al. Hepatitis B and D viruses replication interference: influence of hepatitis B genotype. World J. Gastroenterol. 22, 3165–3174 (2016).

  • 232.

    Kiesslich, D. et al. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J. Infect. Dis. 199, 1608–1611 (2009).

  • 233.

    Schaper, M. et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J. Hepatol. 52, 658–664 (2010).

  • 234.

    Su, C. W. et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 130, 1625–1635 (2006).

  • 235.

    Smedile, A. et al. Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 13, 413–416 (1991).

  • 236.

    Quintero, A. et al. Hepatitis delta virus genotypes I and III circulate associated with hepatitis B virus genotype F in Venezuela. J. Med. Virol. 64, 356–359 (2001).

  • 237.

    Shih, H. H. et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J. Virol. 82, 2250–2264 (2008).

  • 238.

    Vietheer, P. T., Netter, H. J., Sozzi, T. & Bartholomeusz, A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J. Virol. 79, 6570–6573 (2005).

  • 239.

    Colombo, P. et al. Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. J. Hepatol. 12, 64–69 (1991).

  • 240.

    Colagrossi, L. et al. HDV can constrain HBV genetic evolution in HBsAg: implications for the identification of innovative pharmacological targets. Viruses 10, E363 (2018).

  • 241.

    Jilbert, A. J. & Locarnini, S. A. in Viral Hepatitis 3rd edn (eds Thomas, H. C. Lemon, S. & Zuckerman, A. J.) 193–209 (Wiley, 2005).

  • 242.

    Erhardt, A. et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54, 1009–1013 (2005).

  • 243.

    Kao, J. H., Wu, N. H., Chen, P. J., Lai, M. Y. & Chen, D. S. Hepatitis B genotype and the response to interferon therapy. J. Hepatol. 33, 998–1002 (2000).

  • 244.

    Chu, C. J., Hussain, M. & Lok, A. S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122, 1756–1762 (2002).

  • 245.

    Osiowy, C., Gordon, D., Borlang, J., Giles, E. & Villeneuve, J. P. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J. Gen. Virol. 89, 3009–3015 (2008).

  • 246.

    Huy, T. T. T., Ngoc, T. T. & Abe, K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J. Virol. 82, 5657–5663 (2008).

  • 247.

    Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).

  • 248.

    Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat. Methods 14, 587–589 (2017).

  • 249.

    Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2: improving the ultrafast bootstrap approximation. Mol. Biol. Evol. 35, 518–522 (2018).

  • 250.

    Li, J., Buckwold, V. E., Hon, M. W. & Ou, J. H. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J. Virol. 73, 1239–1244 (1999).

  • 251.

    Carman, W. F. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2, 588–591 (1989).

  • 252.

    Okamoto, H. et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J. Virol. 64, 1298–1303 (1990).

  • 253.

    Chotiyaputta, W. & Lok, A. S. Hepatitis B virus variants. Nat. Rev. Gastroenterol. Hepatol. 6, 453–462 (2009).

  • 254.

    Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).

  • 255.

    Li, X. et al. PreS deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection. J. Clin. Virol. 82, 27–32 (2016).

  • 256.

    Lin, C. L. et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22, 1098–1103 (2007).

  • 257.

    Blondot, M. L., Bruss, V. & Kann, M. Intracellular transport and egress of hepatitis B virus. J. Hepatol. 64, S49–S59 (2016).

  • 258.

    Qi, Y. et al. DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 12, e1005893 (2016).

  • 259.

    Walters, K. A., Joyce, M. A., Addison, W. R., Fischer, K. P. & Tyrrell, D. L. Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen. J. Virol. 78, 7925–7937 (2004).

  • 260.

    Ni, Y. et al. The effect of integration on cell susceptibility to HBV and HDV. Presented at the 2019 International Meeting for the Molecular Biology of Hepatitis Viruses (IHBV, 2019).

  • 261.

    Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J. Hepatol. 65, 490–498 (2016).

  • 262.

    Allweiss, L. et al. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with tenofovir in chronic HBV/HDV infected patients: interim results from a multicenter, open-label phase 2b clinical trial [abstract PS-162]. J. Hepatol. 68, S90 (2018).

  • 263.

    Wedemeyer, H. et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection [abstract GS-005]. J. Hepatol. 68, S3 (2018). The final results of the clinical trial that demonstrated treatment with the entry inhibitor Myrcludex B showed efficacy against HDV infection.

  • 264.

    Freitas, N., Cunha, C., Menne, S. & Gudima, S. O. Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J. Virol. 88, 5742–5754 (2014).

  • 265.

    Mason, W. S., Liu, C., Aldrich, C. E., Litwin, S. & Yeh, M. M. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J. Virol. 84, 8308–8315 (2010).

  • 266.

    Tu, T. et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J. Viral Hepat. 22, 737–753 (2015).

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: